Development and Initial Validation of the Chinese Version of the Florida Surgical Questionnaire for Parkinson’s Disease

• Published in: Parkinson's disease Vol. 2020; no. 2020; pp. 1 - 5
• Main Authors: Li, Dianyou, Sun, Bomin, Liu, Jun, Zhang, Chencheng, Wang, Linbin, Pan, Yixin, Zhang, Yiwang, Wang, Tao, Bian, Liuguan
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 12.12.2020; Hindawi; Hindawi Limited; Wiley
• Subjects: Analysis; Atrophy; Candidates; Contraindications; Decision making; Deep brain stimulation; Medical colleges; Medical research; Medicine, Experimental; Movement disorders; Neurodegenerative diseases; Neurosurgery; Parkinson's disease; Patients; Questionnaires; Standard deviation; Surgery; Surveys; Florida; China; United States > US
• ISSN: 2090-8083; 2042-0080
• DOI: 10.1155/2020/8811435

Background. Deep brain stimulation (DBS) for Parkinson’s disease (PD) has evolved as a well-established treatment in neurosurgery, and identifying appropriate surgical candidates could contribute to better DBS outcomes. The Florida Surgical Questionnaire for Parkinson Disease (FLASQ-PD) is a reasonable screening tool for assessing DBS candidacy in PD patients; however, a Chinese version of FLASQ-PD is needed for functional neurosurgery units in China. In this study, we translated the FLASQ-PD to Chinese and assessed its reliability and validity for Chinese PD patients. Methods. The FLASQ-PD was translated before the study formally started. A single-center retrospective analysis of FLASQ-PD was performed at the Ruijin Hospital, affiliated with Shanghai Jiaotong University School of Medicine, between July and December 2019. The Unified Parkinson Disease Rating Scale III (UPDRS-III) was also used to assess PD patients on and off medication. All patients were evaluated for surgical candidacy by specialists. Results. Overall, 115 PD patients, 25 with parkinsonism and six with multiple system atrophy were consecutively included. Internal consistency of the Chinese FLASQ-PD was roughly adequate (Cronbach’s alpha = 0.664). There were significant differences in mean total scores of the Chinese FLASQ-PD between the diagnostic (Kruskal–Wallis H value = 37.450, p≤0.001) and surgery-candidacy groups (H = 48.352, p≤0.001). Drug improvements in UPDRS-III scores were mildly correlated with the Chinese FLASQ-PD scores in the surgery-ready group (Pearson correlation = 0.399, p=0.001). Conclusions. The Chinese FLASQ-PD, which is a simple and efficient screening tool for clinicians, was developed and initially validated in this retrospective single-center study.